WANTAI BIOLOGICAL(SH:603392)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥805,253,559.20, a decrease of 70.40% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2023 was ¥106,006,064.52, down 91.53% year-on-year[3]. - The basic earnings per share for Q3 2023 was ¥0.08, a decline of 92.08% compared to the same period last year[4]. - The net profit attributable to shareholders for the year-to-date period decreased by 54.15% to ¥1,808,364,213.46[3]. - Total operating revenue for the first three quarters of 2023 was CNY 4,968,894,713.90, a decrease from CNY 8,650,520,680.60 in the same period of 2022, representing a decline of approximately 42.5%[27]. - Net profit for the third quarter was CNY 1,811,765,538.11, down from CNY 4,039,308,595.96 in the same quarter of 2022, reflecting a decrease of approximately 55.2%[30]. - The total comprehensive income for the third quarter was CNY 1,811,765,538.11, down from CNY 4,039,308,595.96 in the same quarter of 2022, indicating a decrease of approximately 55.2%[30]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥891,075,081.56, a decrease of 71.37%[4]. - In the first three quarters of 2023, the cash inflow from operating activities was ¥5,282,460,049.00, a decrease from ¥7,045,784,158.72 in the same period of 2022, representing a decline of approximately 25%[31]. - The net cash flow from operating activities for the third quarter of 2023 was ¥891,075,081.56, significantly lower than ¥3,112,862,205.52 in the previous year[32]. - The total cash outflow from operating activities was ¥4,391,384,967.44 in the first three quarters of 2023, compared to ¥3,932,921,953.20 in the same period of 2022, indicating an increase of approximately 11.7%[33]. - The cash flow from operating activities was significantly impacted by a decrease in sales revenue, which fell to ¥5,060,001,699.65 from ¥6,832,443,576.77 in the previous year[31]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥16,464,312,266.40, an increase of 1.45% compared to the end of the previous year[4]. - The company's current assets totaled CNY 11,032,567,946.21, a decrease from CNY 12,179,759,105.13 in the previous year[19]. - The company's total liabilities were CNY 2,763,868,456.76 for current liabilities, down from CNY 3,485,189,792.38 in the previous year[25]. - Non-current liabilities totaled CNY 5,431,744,320.19, compared to CNY 4,049,757,465.99 at the end of 2022, indicating an increase[25]. - The total liabilities as of the end of the third quarter were CNY 2,969,653,761.50, compared to CNY 3,664,624,714.14 in the previous year, indicating a decrease of approximately 19%[28]. - The company's total equity reached CNY 13,494,658,504.90, an increase from CNY 12,564,891,856.98 year-over-year, representing a growth of about 7.4%[28]. Research and Development - The company capitalized research and development expenses related to the nasal spray COVID-19 vaccine in 2022, amounting to ¥4.22 billion, which was fully expensed in 2023[9]. - Research and development expenses for the first three quarters were CNY 812,675,493.88, compared to CNY 379,701,991.30 in the same period of 2022, reflecting an increase of approximately 114.3%[28]. - The company plans to continue its focus on R&D and market expansion despite the current financial challenges[6]. Inventory and Receivables - Accounts receivable stood at CNY 3,973,068,427.90, showing a slight increase from CNY 3,939,517,109.12 year-over-year[19]. - Inventory levels reached CNY 1,121,605,226.85, up from CNY 869,136,666.62, reflecting a significant increase in stock[19]. Investment Activities - The cash inflow from investment activities was ¥2,595,404,232.02 in the first three quarters of 2023, compared to ¥9,540,776,626.04 in the same period of 2022, indicating a decrease of about 72.8%[33]. - The net cash flow from investment activities was -¥1,507,474,676.07 for the first three quarters of 2023, an improvement from -¥2,880,828,622.70 in the same period of 2022[33]. - The cash outflow for investment activities was ¥4,102,878,908.09 in the first three quarters of 2023, compared to ¥3,834,906,248.74 in the same period of 2022, representing an increase of about 7%[33].